Actively Recruiting
Evaluating the Efficacy and Safety of Ixoberogene Soroparvovec Compared to Aflibercept in Adults with Neovascular Age-Related Macular Degeneration
Led by Adverum Biotechnologies, Inc. · Updated on 2026-09-24
534
Participants Needed
79
Research Sites
205 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a gene therapy called Ixo-vec compared to the drug aflibercept in people with neovascular wet age-related macular degeneration nAMD. This degenerative eye disease causes abnormal blood vessel growth under the retina and is a leading cause of vision loss in older adults. The study is a Phase 3 trial including both new and previous treatment patients and aims to see if Ixo-vec is not worse than aflibercept in improving vision. Participants will receive either a single injection of Ixo-vec or multiple injections of aflibercept in the eye. Both groups will begin with three monthly aflibercept injections then one group gets a single Ixo-vec injection and sham injections every 8 weeks, while the other group continues aflibercept every 8 weeks with a sham injection at week 1. The study lasts over a year, with key vision measurements taken around weeks 52 and 56. During the trial, participants will have regular eye exams and assessments of visual acuity and retinal thickness. Researchers will monitor safety, tolerability, and vision changes throughout the study. The main measurement is the average change in best corrected visual acuity at one year. Additional tests include eye imaging and quality of life questionnaires. Participation involves scheduled visits to track treatment effects and side effects over the study duration.
CONDITIONS
Brief Title
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Research Team
A
Adverum Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here